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Abstract
Disruption of lipid and carbohydrate homeostasis is an important factor in the development of prevalent metabolic diseases
such as diabetes, obesity, and atherosclerosis. Therefore, small molecules that could reduce insulin dependence and
regulate dyslipidemia could have a dramatic effect on public health. The grapefruit flavonoid naringenin has been shown to
normalize lipids in diabetes and hypercholesterolemia, as well as inhibit the production of HCV. Here, we demonstrate that
naringenin regulates the activity of nuclear receptors PPARa, PPARc, and LXRa. We show it activates the ligand-binding
domain of both PPARa and PPARc, while inhibiting LXRa in GAL4-fusion reporters. Using TR-FRET, we show that naringenin
is a partial agonist of LXRa, inhibiting its association with Trap220 co-activator in the presence of TO901317. In addition,
naringenin induces the expression of PPARa co-activator, PGC1a. The flavonoid activates PPAR response element (PPRE)
while suppressing LXRa response element (LXRE) in human hepatocytes, translating into the induction of PPAR-regulated
fatty acid oxidation genes such as CYP4A11, ACOX, UCP1 and ApoAI, and inhibition of LXRa-regulated lipogenesis genes,
such as FAS, ABCA1, ABCG1, and HMGR. This effect results in the induction of a fasted-like state in primary rat hepatocytes in
which fatty acid oxidation increases, while cholesterol and bile acid production decreases. Our findings explain the myriad
effects of naringenin and support its continued clinical development. Of note, this is the first description of a non-toxic,
naturally occurring LXRa inhibitor.
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Introduction
The liver is the hub of lipid and carbohydrate homeostasis [1].
Dysregulation of this homeostasis has been implicated in disease
processes, such as atherogenesis, insulin resistance, and hyperme-
tabolism [2,3]. Metabolic conditions, such as insulin resistance, may
be partly attributable to ‘western-style diets’ and are associated with
medical expenditures and lost productivitytotalingover $130billion
annually [4]. Therefore, drugs or dietary supplements that could
potentially reduce insulin dependence and regulate dyslipidemia
could have a dramatic effect on healthcare expenditures and public
health.
One group of compounds previously shown to have hypolip-
idemic and anti-inflammatory properties both in vivo and in vitro are
citrus flavonoids [5,6]. The abundant flavonoid aglycone narin-
genin, which is responsible for the bitter taste in grapefruits, has
been extensively studied in recent years. In vivo studies have
demonstrated its potential as a normolipidemic agent: in a recent
clinical trial, naringenin was shown to reduce circulating levels of
low-density lipoprotein (LDL) by 17% in hypercholesterolemic
patients [7]. Similarly, the cholesterol-lowering effects of narin-
genin have been demonstrated in rabbits [8,9] and rats [10]. In
HepG2 cells, naringenin was shown to reduce the secretion of
VLDL [11,12] through the inhibition of ACAT2 [11] and MTP
[13,14], enzymes critical for VLDL assembly. Naringenin was also
shown to induce LDL-R transcription through PI3K activation
upstream of SREBP-1a [11,14]. Other studies demonstrated that
naringenin inhibited HMG CoA reductase (HMGR), while
activating enzymes important in fatty acid oxidation such as
CYP4A1 [15]. Naringenin’s myriad effects suggest that the
flavonoid may be targeting transcriptional regulation of metabo-
lism through nuclear receptors (NRs), a family of ligand-activated
transcription factors, which play a critical role in the regulation of
lipid metabolism. Strengthening this hypothesis is the anecdotal
report that naringenin binds to LXRa [14] and more recently,
that the flavonoid induces PPRE activity in U-2OS cells [16].
In this study, we demonstrate that naringenin is an agonist of
PPARa and PPARc, and a partial agonist of LXRa. We show that
naringenin induces the activation of PPARa and PPARc ligand-
binding domain (LBD) in GAL4-fusion protein reporters and
PLoS ONE | www.plosone.org 1 August 2010 | Volume 5 | Issue 8 | e12399induces PPRE activity in Huh7.5 human hepatoma cells. Using an
in vitro TR-FRET assay we demonstrate that this interaction does
not change the binding of PGC1a co-activator peptide to
recombinant PPARa ligand binding domain.
Concomitantly, naringenin inhibits the activation of the LXRa
LBD in a GAL4-fusion protein reporter in the presence of the
LXRa agonist TO901317. Using an in vitro TR-FRET assay, we
demonstrate that this effect is mediated by the inhibition of the
binding of the Trap220/Drip-2 co-activator peptide to recombi-
nant LXRa LBD. Expectedly, naringenin also inhibits LXRE
activity in Huh7.5 cells. We show that the induction of PPARa
and inhibition of LXRa induces the expected transcriptional
changes in hepaotcytes, upregulating genes important in fatty acid
oxidation and down-regulating cholesterol and fatty acid synthesis.
These effects result in the induction of a fasted-like state in primary
hepatocytes, in which production of triglycerides and bile acids is
inhibited and ketone body generation increases.
Results
Naringenin activates PPARa and PPARc
The manifold effects of naringenin, include the induction of b-
oxidation [17] and anti-inflammation [5], suggest an underlying
mechanism, similar to the activities of PPARa and PPARc
agonists such as fibrates or thiazolidinediones (TZDs) [18,19].
Therefore, naringenin activation of PPARa and PPARc were
investigated using the previously described HeLa reporter cell
lines, HG5LN GAL4-PPARa and HG5LN GAL4-PPARc [20]. In
these cells, the PPAR LBD is fused to the GAL4 DNA binding
domain and expressed constitutively. Upon binding to an agonist,
the PPAR-GAL4 fusion protein activates a luciferase reporter
[20]. Naringenin dose-dependently activated PPARa reaching
24%60.2% induction at 240 mM( P ,0.001) relative to 1 mMo f
the PPARa agonist GW7647 (Fig. 1a). Furthermore, naringenin
activated PPARc up to 57%60.3% at 80 mM( P ,0.005) relative
to the PPARc agonist 1 mM BRL49653 (Fig. 1b).
To further characterize the interaction between PPARa and
naringenin, a LanthaScreen time-resolved fluorescence resonance
energy transfer (TR-FRET) assay was performed. This cell-free
system measures the ability of a compound to enhance the binding
of a recombinant PPARa LBD to a PGC1a co-activator peptide,
as measured by an increase in TR-FRET signal. While GW7647
showed a clear dose-dependent increase (EC50=2.5nM) in the
binding of PGC1a to PPARa as expected (Fig. 1d), the binding of
PGC1a to PPARa did not increase in the presence of naringenin
(Fig. 1c), suggesting that naringenin’s ability to activate PPARa
does not directly involve enhancement of PPARa LBD binding to
PGC1a.
One possibility is that naringenin induces the transcription of
PGC1a itself, an effect that cannot be seen in the cell-free TR-
FRET assay. Indeed, stimulation of Huh7 cells with 380 mM
naringenin for 24 hours increased PGC1a mRNA abundance by
14-fold (p=0.001) compared to DMSO-treated controls.
Naringenin is a partial agonist of LXRa
Our group and others have shown that naringenin inhibits
HMGR, an enzyme controlled by SREBP1c and in turn by the
LXRa [21,22]. In fact, there are some indications that naringenin
binds LXRa in vitro [23]. To test naringenin’s capacity to function
as an LXRa antagonist, LXR-alpha-UAS-bla HEK 293T cells
were stimulated with 4.7 nM TO901317 (corresponding to
TO901217 EC80) and then treated with increasing concentrations
of naringenin. Naringenin dose-dependently inhibited LXRa
activity, reaching 28.4%60.4% (p,0.01) and 39.1%69.4%
(p,0.05) at concentrations of 126 mM and 400 mM, respectively
(Fig. 2a).
Figure 1. Naringenin induces activation of PPARa and PPARc ligand-binding domains. HG5LN reporter cells expressing GAL4-PPARa (a)
and GAL4-PPARc (b) reporters were treated with increasing concentrations of naringenin. Naringenin dose-dependently activated PPARa reaching
24%60.2% induction at 240 mM( P ,0.001); and activated PPARc up to 57%60.3% at 80 mM( P ,0.005). Data is presented as percent activation
relative to 1 mM of classical agonists GW7647 and BRL49653, respectively. (c) LanthaScreen TR-FRET assay, demonstrating that naringenin did not
affect the binding of the PGC1a co-activator peptide to recombinant PPARa LBD. (d) In contrast, the classical PPARa agonist GW7647 induces a dose-
dependent binding of PGC1a to PPARa in the same assay.
doi:10.1371/journal.pone.0012399.g001
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characterized using a Lanthascreen TR-FRET assay. Naringenin
enhanced the binding of the LXRa LBD to the Trap 220/Drip-2
co-activator moderately, yet significantly, in a dose-dependent
manner reaching 38.0%62.8% activation (Fig. 2b) compared to
the well-studied LXRa agonist, TO901317 (Fig. 2c). Notably, in
the presence of 1 mM TO901317 (corresponding to TO901317
EC80), naringenin dose-dependently inhibited the binding of the
Trap 220/Drip-2 co-activator to the LXRa LBD, reaching
11.6%63% inhibition (p,0.01) at 133 mM( Fig. 3d). These
results suggest that naringenin is a ligand and a partial agonist of
LXRa.
Naringenin induces PPRE and inhibits LXRE activity in
hepatocytes
To explore the effect of naringenin on PPAR activation in
hepatocytes, we quantified the activation of a PPAR response
element (PPRE)-reporter in Huh7 cells. Naringenin treatment
significantly and dose-dependently enhanced PPRE activity,
reaching 17%64% (p,0.01) at 150 mM( Fig. 3a). Similar levels
of activation were observed when cells were exposed to the known
PPAR agonists, WY14,643 (10%65%) and ciglitazone (24%6
5%). Notably, at 200 mM naringenin induction of PPRE was not
significantly different then 10 mM WY14,643 (p=0.25).
To test the ability of naringenin to inhibit LXRa activity in
hepatocytes, we quantified the activation of LXR response
element (LXRE)-reporter in Huh7 cells. Naringenin treatment
significantly and dose-dependently decreased LXRE acitivty,
reaching a 50.3%62.6% inhibition at 150 mM( p ,0.001;
Fig 3c). By comparison, a recently published LXRa-specific
antagonist, 5CPPSS-50 failed to inhibit LXRE activity under the
same conditions (Supp. Fig. 1) and led to significant toxicity at
higher doses.
Naringenin-induced Gene and Metabolic changes in
hepatocytes
To assess if PPARa activation by naringenin leads to induction
of PPARa-regulated genes we stimulation Huh7 cells with 200 mM
naringenin for 24 hours and quantified mRNA abuandance by
qRT-PCR. Naringenin induced the expression of fatty acid
oxidation genes CYP4A11, ACOX, UCP1 and ApoAI by 68%,
31%, 60%, and 25%, respectively (Fig. 3b). On the other hand,
naringenin reduced the mRNA abuandance of LXRa-regulated
genes ABCA1, ABCG1, HMGR, and FASN by 92%, 27%, 43%,
and 41% respectively (Fig. 3d). These results suggest a shift from
lipogensis and cholesterol synthesis to lipolysis.
Interestingly, Huff and coworkers previously demonstrated that
naringenin activated SREBP1a-dependent LDLR expresion
[11,14]. As SREBP is regulated by LXRa we studied the gene
expression of SREBP1/2 regulated LDLR and HMGCS promot-
ers in Huh7 cells using reporter constructs. We show that
naringenin increases LDLR transcription by 26%611%, but
decreases HMGCS transcription by 13%63% (Fig 4d). HMGCS
is regulated by SREBP2 rather than SREBP1 and like HMGR
plays a role in cholesterol synthesis.
ApoB100 is the structural protein of VLDL whose production is
blocked by naringenin [21]. As our results suggest that naringenin
acts through PPARa induction, we examined whether PPARa and
PPARc agonists, affected ApoB100 secretion. Huh7 cells were
stimulated with 200 mM naringenin, 10 mM WY14,643, or 10 mM
ciglitazone for 24 hours. Predictably, naringenin led to a
73%69% (p,0.001) reduction in ApoB production (Fig. 4a)
Figure 2. Naringenin is a partial agonist of LXRa ligand-binding domain. (a) LXR-alpha-UAS-bla HEK 293T cells were stimulated with 4.7 nM
TO901317 and exposed to increasing concentrations of naringenin. Naringenin dose-dependently inhibited LXRa activity, reaching 28.4%60.4%
(p,0.01) and 39.1%69.4% (p,0.05) at concentrations of 126 mM and 400 mM, respectively. (b-d) Lanthascreen TR-FRET assay, demonstrating that
naringenin weakly increased the binding of Trap 220/Drip-2 co-activator peptide to recombinant LXRa LBD, and inhibited this binding in the
presence of TO901317, LXRa classical agonist. (b) Naringenin is a weak agonist, enhancing the binding of the LXRa LBD to the Trap 220/Drip-2 co-
activator moderately, yet significantly, in a dose-dependent manner reaching 38.0%62.8% activation. (c) LXRa agonist TO901317 strongly enhanced
co-activator binding. (d) When treated with 250 nM TO901317, increasing concentrations of naringenin led to an inhibition of the TR-FRET signal,
reaching 15.0%64.1% inhibition (p,0.01) at 133 mM.
doi:10.1371/journal.pone.0012399.g002
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dependently enhanced PPRE activity, in Huh7 cells transiently transfected with a PPRE reporter, reaching 17%67% (p,0.05) at 200 mM. Induction was
not different from PPAR agonists WY14,643 and ciglitazone. (b) Naringenin induced the expression of PPARa coactivator PGC1a by 14-fold (p=0.001)
as well as PPARa-regulated fatty acid oxidation genes CYP4A11/22, ACOX, UCP1 and ApoAI. Huh7 cells were treated with naringenin for 24 hours and
mRNA isolated and anlysed by qRT-PCR. (c) Naringenin dose-dependently suppressed LXRE activity, in Huh7 cells transiently transfected with a LXRE
reporter, reaching a 50.3%62.6% (p,0.001) inhibition at 150 mM. (d) Naringenin inhibited the expression of LXRa-regulated lipogenesis genes
ABCA1, ABCG1, HMGR, and FASN. Cell viability under all conidtions was greater than 95%.
doi:10.1371/journal.pone.0012399.g003
Figure 4. Naringenin induced a fasted-like state in hepatic lipid metabolism. (a) Huh7 cells were stimulated for 24 hours with 200 mM
naringenin, 10 mM WY14,643, or 10 mM ciglitazone. Naringenin treatment led to a 73%69% (p,0.001) reduction in ApoB production, while WY14,643
led to a 33%612% (p,0.01) reduction. Treatment with cigilitazone did not lead to a significant change in VLDL production. (b) Primary rat
hepatocytes were stimulated with 200 mM naringenin or 10 mM WY14,643. Naringenin treatment led to a 61% (p,0.001) reduction in triglyceride
production and 17% increase in ketone body formation, not different from WY14,643. However, naringenin treatment led to a 32%611% (p=0.005)
reduction in bile salt production, while WY14,643 did not. Urea accumulation in the media did not change significantly. (c) Intracellular levels of
triglycerides in primary rat hepatocytes stimulated with naringenin. A slight decrease is observed. (d) Naringenin effect on SRE-driven gene
expression. We show that naringein induces LDLR transcription by 26% (p=0.02) while inhibiting HMGCS transcription by 13% (p=0.001). It is
thought that each promoter is regulated by a different SREBP isoform.
doi:10.1371/journal.pone.0012399.g004
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agonist WY14,643. Cigilitazone did not lead to a significant
change in ApoB secretion.
Lastly, we characterized the metabolic changes induced by
naringenin on primary hepatocytes. Primary rat hepatocytes were
stimulated with 200 mM naringenin or 10 mM WY14,643 for
24 hours and culture media was analyzed for changes in urea,
triglycerides, bile acid, and ketone bodies (Fig. 4b). As could be
expected, primary hepatocytes showed no change in urea
production. However, both naringenin and WY14,643 led to a
61% (p,0.001) and 41% (p,0.05) reduction in triglyceride
production, respectively (Fig. 4b). Ketone body production was
only slightly elevated by 17% and 23%, respectively. Importantly,
no increase in intracellular levels of triglycerides were found
(Fig. 4c) suggesting this inhibition was a result of increased fatty
acid oxidation in primary hepatocytes. Interestingly, while PPARa
agonist WY14,643 did not have an effect on hepatic bile acid
production, naringenin cased a significant 32%611% (p=0.005)
reduction in bile salt production (Fig. 4b), possibly due to
inhibition of cholesterol synthesis, through suppression of LXRa
[24,25].
Discussion
Dysregulation of lipid homeostasis is associated with multiple
disease states, including metabolic, inflammatory, and infectious
disorders [26]. Metabolic regulation is achieved in mammals
through an intricate transcriptional mechanism responding to
physiological cues. In recent years, a family of ligand-activated
transcription factors called nuclear receptors emerged as key
regulators of cellular metabolism [25,27,28]. Previously defined as
orphan receptors, key metabolites were shown to be the natural
ligands of many nuclear receptors, including liver X receptors
(LXRs) which respond to oxysterols and glucose [29,30], farnesoid
X receptor (FXR) which responds to bile acids [31], and the
peroxisome proliferator-activated receptors (PPARs) which re-
spond to fatty acids [32].
The PPAR family includes PPARa, PPARc, and PPARd. The
prevalence of these receptor subtypes varies in different tissues,
with PPARa being the most prevalent subtype in the liver, and
PPARc the most abundant in adipose tissue [18]. PPARa is
activated by fatty acids released in a physiological fasting state,
leading to increased b-oxidation and gluconeogenesis [33,34]. In
clinical practice, PPARa agonists (fibrates) are used to treat
hyperlipidemia, whereas PPARc agonists (TZDs) are used to
increase insulin sensitivity in muscle and adipose tissue [19,35].
The LXR family includes both LXRa and LXRb [29,30,36]. The
latter is ubiquitously expressed, while the former is found primarily
in the liver, adipose tissue, and macrophages and is activated by
glucose and sterols [37], typical of a physiological fed state. In the
liver, following activation by its ligands, LXRa activates lipogenic
and glycolytic genes partly through activation of SREBP [38,39].
HMGR, the target of statins, is regulated through this pathway
controlling cholesterol availability for bile acid synthesis in
hepatocytes.
Following a ligand binding event, both PPARs and LXRs
become activated and heterodimerize with the retinoid X receptor
(RXR) [27]. This heterodimer then binds conserved response
elements such as PPRE or LXRE, while recruiting other co-
regulatory molecules, such as the co-activators PGC1a [40] and
Trap220 [41] for PPARa and LXRa, respectively. The require-
ment of a RXR binding partner leads to competitive inhibition at
the level of receptor activation, offering a transcriptional layer of
control over fasted-to-fed transition [42,43,44]. The existence of
both a PPAR response element (PPRE) and an LXR response
element (LXRE) in the regulatory region of LXRa [45,46]
suggests further levels of cross-regulation. Lastly, other coactiva-
tors, corepressors and kinases, such as PI3K and ERK, can
regulate nuclear receptor activity by non-transcriptional mecha-
nisms [47,48,49].
Naringenin is an aglycone of the grapefruit flavonoid naringin,
which is responsible for the bitter taste in grapefruit. Naringenin
has been reported to be an antioxidant with hypolipidemic, anti-
carcinogenic and anti-inflammatory properties both in vivo and in
vitro [5,7,8,9,10].The flavonoid was shown to reduce VLDL
secretion [50,51] through inhibition of ACAT2 and MTP [50,52],
critical enzymes for VLDL assembly. Allister et al. demonstrated
that this inhibition is regulated through the MAPK/ERK pathway
[52]. In addition, naringenin was shown to upregulate SREBP-
dependent LDLR through PI3K activation [23]. Naringenin has
also been shown to inhibit SREBP-dependent HMGR [53], while
activating enzymes important in fatty acid oxidation such as
CYP4A1 [54]. These myriad effects suggest that the flavonoid’s
target might be at the nuclear receptor level. Strengthening this
hypothesis is the anecdotal report that naringenin binds to LXRa
[23] and, more recently, that it induces PPRE activity in U-2OS
cells [55].
In this work we demonstrate that naringenin activates the LBD
of both PPARa and PPARc using a reporter cell line over
expressing GAL4 fusion proteins to either PPARa LBD or PPARc
LBD [20]. Activation of PPAR LBD releases the complex and
allows it to bind the UASG response element, expressing luciferase.
This reporter system demonstrates that naringenin acts on the
LBD of both PPARa and PPARc (Fig. 1), suggesting it serves as a
natural ligand. However, the TR-FRET assay suggests that
naringenin does not induce a conformational change in PPARa
LBD like other ligands, such as GW7647, failing to increase its
binding to the PGC1a co-activator (Fig. 1). One possibility is that
naringenin induces a different conformational change in the
PPARa LBD that recruits another co-activator, not found in the
cell-free TR-FRET assay. However, a more likely scenario is that
naringenin induces PPARa phosphorylation or alternately,
PGC1a expression. Indeed our data shows that naringenin
stimulation increases the mRNA abundance of PGC1a in Huh7
cells by 14-fold. Regardless of the exact nature of the interaction,
naringenin-induced PPARa activation, lead to increased PPRE
activity in human hepatocytes (Fig. 3a) and the expression of
PPARa-regulated genes (Fig. 3b).
Concomitantly with PPARa activation, we show that narin-
genin inhibits the activity of LXRa. Using a similar reporter cell
line over expressing the GAL4 fusion protein with LXRa LBD, we
show a significant inhibition of LXRa LBD in the presence of
TO901317, a classical agonist (Fig. 2). In contrast to the PPARa
findings, we show that naringenin specifically increases the
interaction of the Trap-220 co-activator with LXRa LBD in the
cell-free TR-FRET assay. Interestingly, in the presence of LXRa
agonist TO901317, naringenin actually decreased the interaction
of Trap-220 with the LXRa LBD, demonstrating it is a partial
agonist of LXRa naturally leading to a competitive inhibition of
LXRa activity. This conclusion is further supported by the
decrease in LXRE activity in human hepatocytes (Fig 3c) and the
down-regulation of LXRa target genes (Fig. 3d).
The metabolic effect of PPARa induction and LXRa inhibition
by naringenin are shown on gene expression (Fig. 3) and
functional levels (Fig. 4). The mRNA abundance of PPARa-
target genes that control fatty acid oxidation, such as CYP4A11,
ACOX, and UCP1 significantly increases in human hepatoma
cells. As lipid metabolism of hepatoma cell lines is dramatically
Naringenin: PPARa and LXRa
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aspects of PPARa and LXRa regulation in primary rat
hepatocytes. As could be expected, both naringenin and PPARa
agonist, WY14,643 led to a similar decrease in triglyceride
production and an increase in ketone body secretion (Fig. 4b).
Intracellular levels of hepatic triglycerides were also slightly
reduced (Fig. 4c). Interestingly, naringenin caused a much steeper
73% decrease in VLDL secretion compared to 33% decrease by
WY14,643 (Fig. 4a). This difference was significant (p=0.006),
and could possibly be due to inhibition of cholesterol synthesis
through LXRa.
Indeed, the mRNA abundance of LXRa-target genes that
regulates fatty acid and cholesterol synthesis, such as ABCA1,
ABCG1, HMGR, and FASN decreses (Fig. 3d). While cholesterol
production could not be detected in our system (data not shown),
cholesterol serves as the percuror of hepatic bile acids. Interestingly,
LXRa activation was shown to drive bile synthesis in rats [24,25].
Therefore, the 32% decrease in bile acids prodcution following
naringenin stimulation (Fig. 4b) serves as a surrogate measure of
choelsterol production. WY14,643 which upregulates PPARa
without effecting LXRa, showed no such change. Regretfully, no
reliable LXRa inhibitor is commercially available, and 5CPPSS-50
showedsignificanttoxicityinourhands(Fig.S1).Preliminaryresults
using siRNA to LXRa show some inhibition of bile acid and VLDL
production, although results were inconclusive (data not shown).
We note that the GAL4 fusion reporter data suggests that in-
spite of the well known cross-regulation between PPARa and
LXRa [42,43,44], naringenin appears to acts independently on
each of these nuclear receptors. This is another indication of the
nuclear receptor family promiscuity, and suggests that complex
metabolic programs could be induced by relatively few com-
pounds. Indeed, dual PPARa and PPARc agonists have recently
been investigated as normoglycemic and antiatherogenic agents
[56]. Naringenin activation of both PPARa and PPARc suggests a
similar ability to regulate insulin sensitivity and LDL levels.
However, in contrast to other dual PPAR agonists, such as
Aleglitazar, our work shows naringenin is also an LXRa inhibitor.
The metabolic program provoked by naringenin, appears to be a
fed-to-fasted transition in the lipid metabolism of primary hepato-
cytes. Naringenin not only increases fatty acid oxidation but also
inhibit fatty acid and cholesterol synthesis.
The potential of using a naturally occurring dietary supplement
to regulate lipid metabolism is appealing as this by product of the
grapefruit juice industry is non-toxic, cheap, and has demonstrated
anti-inflammatory properties. This is especially important in the
context of the rising costs of cardiovascular care, estimated by the
AHA to rise above $500 billion this year. Naringenin ability to
inhibit HMGR, the target of statins, while upregulating PPARa,
the target of fibrates, suggest it can naturally find its place in the
routine treatment of hyperlipidemia.
Finally, our group and other have shown that the Hepatitis C
Virus (HCV) is critically dependent on host lipid metabolism
[21,57,58]. Similar interplays were shown for the Hepatitis B
Virus (HBV) [59,60]. Therefore, compounds that modulate
hepatic lipid metabolism could have significant antiviral effect.
And indeed, our work shows that naringenin blocks HCV
production from Huh7.5.1/JFH1 infected cells [21]. These
findings form the basis of a currently conducted clinical trial to
explore naringenin inhibition of HCV production in non-
responding patients. Interestingly, the anti-inflammatory proper-
ties of naringenin could be readily explained in the context of
PPAR activation. Such properties could have a significant effect
on liver inflammation, preventing or delaying the development of
hepatosteatosis and cancer [61].
Materials and Methods
Reagents
Fetal bovine serum (FBS), phosphate-buffered saline (PBS),
Dulbecco’s modified Eagle medium (DMEM), penicillin, strep-
tomycin, trypsin-ethylene diamine tetraacetic acid (EDTA),
OptiMEM basal medium, and Lipofectamine 2000 were
obtained from Invitrogen Life Technologies (Carlsbad, CA).
Insulin was obtained from Eli-Lilly (Indianapolis, IN). Dual
luciferase assay kit was purchased from Promega (Madison, WI).
The reported LXRa antagonist 5CPPSS-50 [62] was a kind gift
of Dr. Hashimoto (The University of Tokyo). Unless otherwise
noted, all other chemicals were purchased from Sigma-Aldrich
Chemicals (St. Louis, MO).
Cell culture
Huh7 cells were a kind gift of Prof. Raymong Chung,
Massachusetts General Hospital. The cells were cultured in
DMEM supplemented with 10% FBS, and 200 units/mL
penicillin and streptomycin in a 5% CO2-humidified incubator
at 37uC. Huh7 cells were passaged every 3 days and used at
passage ,15.
GAL4-nuclear receptor activation assays
Activation of PPAR LBD was quantified using the previously
described HGLN5 PPARa and PPARc cell line [20]. Briefly,
HeLa cells were stably transfected with the p(GAL4RE)5-bGlob-
Luc-SVNeo plasmid, encoding the firefly luciferase gene driven by
a pentamer of yeast activator GAL4 binding sites in front of b-
globin promoter [20]. Cells were subsequently stably transfected
with either pGAL4-PPARa-puro, or pGAL4-PPARc-puro, en-
coding amino acids 1–147 of GAL4, followed by a short linker and
the LBD of either PPARa or PPARc, respectively [20]. HGLN5
cells were seeded at a density of 100,000 cells/cm
2, test
compounds were added 8 hours later and incubated for 16 hours.
Following treatment, cells were washed with PBS and lysed in
25 mM Tris buffer (pH 7.8). Protein concentration was calculated
using the Bradford assay and used to normalize the luciferase
activity. Finally, activation of PPARa and PPARc reporters is
presented as percent of maximal activation by the known agonists
GW7647 and BRL49653, respectively.
LXRa activation was investigated using the GeneBLAzer Beta-
lactamase reporter technology (Invitrogen SelectScreen Cell-Based
Nuclear Receptor Profiling Service, Madison, WI). LXR-alpha-
UAS-bla HEK 293T cells were thawed and resuspended in Assay
Media (DMEM phenol red free, 2% CD-treated FBS, 0.1 mM
NEAA, 1 mM sodium pyruvate, 100 units/mL penicillin and
streptomycin) to a concentration of 312,500 cells/mL. The control
agonist TO901317 at the pre-determined EC80 concentration
(5 nM) was added to wells containing variable concentrations of
naringenin. The plate was incubated for 16–24 hours at 37uC and
5% CO2 in a humidified incubator. Substrate loading solution was
added to each well and the plate is incubated for 2 hours at room
temperature. The plate is read on a fluorescence plate reader.
Results for each concentration (n=4) are reported as percent
activation of TO901317-stimulated, naringenin-free controls.
TR-FRET Assays
LanthaScreen TR-FRET Coactivator Assays, purchased from
Invitrogen (Madison, WI), were used to identify agonists and
antagonists of PPARa and of LXRa. In these cell-free assays,
ligands are identified by their ability to bind the recombinant
LBD of the respective receptor and induce a conformational
change that results in recruitment of a fluorescein-labeled
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tagged PPAR alpha or LXRa LBD is indirectly labeled using a
terbium-labeled anti-GST tag antibody. Recruitment of fluo-
rescein-labeled coactivator peptide – PGC1a for PPARa or
Trap220 for LXRa – is measured by monitoring fluorescence
resonance energy transfer (FRET) from the terbium-labeled
antibody to the fluorescein on the peptide, resulting in a high
TR-FRET ratio (520/490 nm emission). Test compounds were
diluted in DMSO, and assays were run per the manufacturer’s
instructions. Briefly, to test the ability of a molecule to function
as an agonist, increasing concentrations of naringenin or control
agonist were added to LBD and co-activator peptide solutions.
To test the ability of a molecule to function as an antgonist, a
similar protocol was followed, but 250 nM TO901317 (EC80 of
the agonist, measured in this assay) was added to all wells. In
both agonist and antagonist modes, following 1 to 2 hour
incubation at room temperature, the 520/490 TR-FRET ratio
was measured with a PerkinElmer Envision fluorescent plate
reader with TRF laser excitation using the following filter set:
excitation 330 nm, emission 495 nm, and emission 520 nm. A
100 msec delay followed by a 200 msec integration time was used
to collect the time-resolved signal. Results are displayed as
percent activation compared to maximal activation of positive
control.
PPAR and LXRa response element luciferase reporter
assays
Activation of PPRE and LXRE was quantified by transiently
transfecting Huh7 cells with previously described firefly luciferase
reporter plasmids, pACOX(62)luc and pDR4(62)luc, respective-
ly [44,63]. The pRL-TK plasmid (Promega, Madison, WI),
constitutively expressing renilla luciferase, was co-transfected as
positive control. pACOX(62)luc was transfected into Huh7 cells
cultured in OptiMEM. After 22 hours of culture, cells were
stimulated with naringenin, WY14,643, or ciglitizone for
24 hours in standard culture medium. To quantify LXRE
activity, cells were similarly transfected and treated with
naringenin, 5CPPSS-50, or TO901317. Ratio of firefly to renilla
luciferase luminescence was quantified using a Dual Luciferase
Assay kit (Promega) following the manufacturer’s instructions.
DMSO levels were equal in all samples and never exceeded
0.5%. Results are reported as percent activation compared to
DMSO-only controls.
Quantitative Real Time Polymerase Chain Reaction
(qRT-PCR)
Following a 24-hour stimulation, cells were lysed with RLT Plus
buffer containing b-mercaptoethanol and RNA was isolated using
RNeasy Mini Kit on a QIACube device (Qiagen, Valencia, CA).
Total RNA was quantified on a ND-1000 spectrophotometer
(NanoDrop Technologies, Rockland, Del.) and mRNA transcript
abundance was measured on a MyiQ Real-Time PCR Detection
System using iScript One-Step RT-PCR Kit With SYBR Green
(Bio-Rad, Hercules, CA), according to the manufacturers’
instructions. Primers used in these reactions (Integrated DNA
Technologies, Coralville, IA) were designed using the PRIMER-
BLAST program and appear in Table 1.
Human ApoB Enzyme-Linked Immunosorbent Assay
(ELISA)
Huh7-secreted ApoB-100 was detected using ALerCHEK, Inc.
(Portland, ME), total human ApoB-100 ELISA kit. The medium
was diluted 1:10 with the specimen diluent, and the assay was
carried out according to the manufacturer’s directions.
Analysis of metabolic changes in primary rat hepatocytes
Primary rat hepatocytes were harvested from adult female Lewis
rats purchased from Charles River Laboratories, as previously
described Hepatocyte viability was greater than 90% and purity
above 95%. [64]. All animals were treated in accordance with
National Research Council guidelines and approved by the
Subcommittee on Research Animal Care at the Massachusetts
General Hospital (IACUC #2005N000109). Cells were seeded on
collagen-coated dishes at a density of 150,000 cells/cm
2 under
serum-free conditions, using 100 mL/mL soluble collagen type-I as
attachment factor. Serum-free hepatocyte culture medium was
purchased from Lonza (Walkersville, MD). Cells were stimulated
with naringenin or WY14,643 for 24 hours, and cell culture
medium was collected for metabolic analysis. Cell pellet was
collected for intracellular triglyceride and total protein determi-
nation.
Urea concentration was measured using diacetylmonoxime
methodology using a commercial available Blood Urea Nitrogen
kit (Stanbio Labs, Boerne, TX). Triglycerides, in the culture
medium and cell extracts, were quantified using a commercial kit
(Sigma Chemical, St.Louis, MO) based on enzymatic hydrolysis
by lipase to glycerol. Ketone bodies, were measured based on the
appearance of NADH in conversion to acetoacetate in presence
of b-hydroxybutyrate dehydrogenase (Zupke et al.1998). Total
cholesterol was measured by a commercial available kit
(StandBio Labs) based on the reaction of free cholesterol and
cholesterol esters with cholesterol oxidase. Bile acids were
determined through the formation of NADH in presence of
the enzyme 3-a-hydroxysteroid dehydrogenase (Bio-Quant, San
Diego, CA).
Table 1. Real-Time qRT-PCR Primers.
Gene Primers
PPARa ACG CTT TCA CCA GCT TCG AG
GAA AGA AGC CCT TGC AGC CT
CYP4A11/22 ACT GGC TCT TCG GGC ACA TC
ACA CGA ACT TTG CCT CCC CA
ACOX TGG CAC ATA CGT GAA ACC GC
CGC TGT ATC GGA TGG CAA TG
ApoAI AAA GCT GCG GTG CTG ACC TT
CGC TGT CTT TGA GCA CAT CCA
LXRa GCT CCT TTT CTG ACC GGC TT
TGA ATT CCA CTT GCA GCC CT
ABCA1 TCT GGA AAG CTC TGA AGC CG
TGA GTT CCT CCC ACA TGC CT
ABCG1 ACC GGG GAA AAG TCT GCA AT
TCA CCA GCC GAC TGT TCT GA
HMGR GAC CCC TTT GCT TAG ATG AA
GGA CTG GAA ACG GAT ATA AA
FASN TTG CAG GGA GAC CTG GTG AT
GGT GAG GGT GCT CAC AAA GG
PGC1a GGC AGA AGA GCC GTC TCT ACT TA
TTT GCA TGG TTC TGG GTA CTG A
doi:10.1371/journal.pone.0012399.t001
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Data are expressed as the mean 6 standard deviation.
Statistical significance was determined by a one-tailed Student’s
t-test. A P-value of 0.05 was used for statistical significance.
Supporting Information
Figure S1 5CPPSS-50 led to no change in LXRE activity. In all
experiments, Renilla luciferase was used to account for variability
in transfection efficiencies.
Found at: doi:10.1371/journal.pone.0012399.s001 (3.87 MB TIF)
Acknowledgments
The authors wish to thank Candice Calhoun for technical assistance, Prof.
Raymond T. Chung and Dr. Alejandro Soto-Gutierrez for important
discussion.
Author Contributions
Conceived and designed the experiments: JG YN. Performed the
experiments: JG PYC EY PB YN. Analyzed the data: JG PYC YN.
Contributed reagents/materials/analysis tools: PB MLY YN. Wrote the
paper: JG YN.
References
1. McGarry JD, Foster DW (1980) Regulation of hepatic fatty acid oxidation and
ketone body production. Annu Rev Biochem 49: 395–420.
2. Gastaldelli A, Kozakova M, Hojlund K, Flyvbjerg A, Favuzzi A, et al. (2009)
Fatty liver is associated with insulin resistance, risk of coronary heart disease, and
early atherosclerosis in a large European population. Hepatology 49:
1537–1544.
3. Buchman A, Korenblatt K, Klein S (2006) Nutrition and the Liver. In: Schiff ER,
Sorrell MF, Maddrey WC, eds. Schiff’s diseases of the liver. Philadelphia:
Lippincott, Wiliams, and Wilkins Co.
4. Hogan P, Dall T, Nikolov P, Association AD (2003) Economic costs of diabetes
in the US in 2002. Diabetes Care 26: 917–932.
5. Wilcox LJ, Borradaile NM, Huff MW (1999) Antiatherogenic Properties of
Naringenin, a Citrus Flavonoid. Cardiovascular Drug Reviews 17: 160–178.
6. Crozier A, Jaganath IB, Clifford MN (2009) Dietary phenolics: chemistry,
bioavailability and effects on health. Natural product reports 26: 1001–1043.
7. Jung UJ, Kim HJ, Lee JS, Lee MK, Kim HO, et al. (2003) Naringin
supplementation lowers plasma lipids and enhances erythrocyte antioxidant
enzyme activities in hypercholesterolemic subjects. Clinical Nutrition 22:
561–568.
8. Kurowska E, Borradaile N, Spence JD, Carroll KK (2000) Hypocholesterolemic
effects of dietary citrus juices in rabbits. Nutr Res 20: 121–129.
9. Lee C-H, Jeong T-S, Choi Y-K, Hyun B-H, Oh G-T, et al. (2001) Anti-
atherogenic effect of citrus flavonoids, naringin and naringenin, associated with
hepatic ACAT and aortic VCAM-1 and MCP-1 in high cholesterol-fed rabbits.
Biochem Biophys Res Commun 284: 681–688.
10. Kim S-Y, Kim H-J, Lee M-K, Jeon S-M, Do G-M, et al. (2006) Naringin time-
dependently lowers hepatic cholesterol biosynthesis and plasma cholesterol in
rats fed high-fat and high-cholesterol diet. J Med Food 9: 582–586.
11. Wilcox LJ, Borradaile NM, Dreu LEd, Huff MW (2001) Secretion of hepatocyte
apoB is inhibited by the flavonoids, naringenin and hesperetin, via reduced
activity and expression of ACAT2 and MTP. Journal of Lipid Research 42:
725–734.
12. Kurowska EM, Manthey JA, Casaschi A, Theriault AG (2004) Modulation of
HepG2 Cell Net Apolipoprotein B Secretion by the Citrus Polymethoxyflavone,
Tangeretin. Lipids 39: 143–151.
13. Borradaile NM, Dreu LEd, Barrett PHR, Huff MW (2002) Inhibition of
hepatocyte apoB secretion by naringenin: enhanced rapid intracellular
degradation independent of reduced microsomal cholesteryl esters. Journal of
Lipid Research 43: 1544–1554.
14. Borradaile NM, Dreu LEd, Huff MW (2003) Inhibition of Net HepG2 Cell
Apolipoprotein B Secretion by the Citrus Flavonoid Naringenin Involves
Activation of Phosphatidylinositol 3-Kinase, Independent of Insulin Receptor
Substrate-1 Phosphorylation. Diabetes 52: 2554–2561.
15. Huong DT, Takahashi Y, Ide T (2006) Activity and mRNA levels of enzymes
involved in hepatic fatty acid oxidation in mice fed citrus flavonoids. Nutrition
22: 546–552.
16. Liu L, Shan S, Zhang K, Ning Z-Q, Lu X-P, et al. (2008) Naringenin and
Hesperetin, Two Flavonoids Derived from Citrus aurantium Up-regulate
Transcription of Adiponectin. Phytotherapy Research 22: 1400–1403.
17. Mulvihill EE, Allister EM, Sutherland BG, Telford DE, Sawyez CG, et al. (2009)
Naringenin prevents dyslipidemia, apoB overproduction and hyperinsulinemia
in LDL-receptor null mice with diet-induced insulin resistance. Diabetes.
18. Lee C-H, Olson P, Evans RM (2003) Minireview: lipid metabolism, metabolic
diseases, and peroxisome proliferator-activated receptors. Endocrinology 144:
2201–2207.
19. Gervois P, Fruchart J, Staels B (2007) Drug Insight: mechanisms of action and
therapeutic applications for agonists of peroxisome proliferator-activated
receptors. Nature clinical practice Endocrinology & metabolism 3: 145–156.
20. Seimandi M, Lemaire G, Pillon A, Perrin A, Carlavan I, et al. (2005) Differential
responses of PPARalpha, PPARdelta, and PPARgamma reporter cell lines to
selective PPAR synthetic ligands. Anal Biochem 344: 8–15.
21. Nahmias Y, Goldwasser J, Casali M, van Poll D, Wakita T, et al. (2008)
Apolipoprotein B-dependent hepatitis C virus secretion is inhibited by the
grapefruit flavonoid naringenin. Hepatology 47: 1437–1445.
22. Lee SH, Park YB, Bae KH, Bok SH, Kwon YK, et al. (1999) Cholesterol-
lowering activity of naringenin via inhibition of 3-hydroxy-3-methylglutaryl
coenzyme A reductase and acyl coenzyme A:cholesterol acyltransferase in rats.
Ann Nutr Metab 43: 173–180.
23. Borradaile NM, de Dreu LE, Huff MW (2003) Inhibition of net HepG2 cell
apolipoprotein B secretion by the citrus flavonoid naringenin involves activation
of phosphatidylinositol 3-kinase, independent of insulin receptor substrate-1
phosphorylation. Diabetes 52: 2554–2561.
24. Gupta S, Pandak WM, Hylemon PB (2002) LXR alpha is the dominant
regulator of CYP7A1 transcription. Biochem Biophys Res Commun 293:
338–343.
25. di Fabiani E, Crestani M, Mitro N (2004) Lipid-activated nuclear receptors:
from gene transcription to the control of cellular metabolism. Eur J Lipid Sci
Technol 106: 432–450.
26. Mittra S, Bansal VS, Bhatnagar PK (2008) From a glucocentric to a lipocentric
approach towards metabolic syndrome. Drug Discovery Today 13: 211–218.
27. Gronemeyer H, Gustafsson JA, Laudet V (2004) Principles for modulation of the
nuclear receptor superfamily. Nat Rev Drug Discov 3: 950–964.
28. Ory DS (2004) Nuclear receptor signaling in the control of cholesterol
homeostasis: have the orphans found a home? Circulation Research 95:
660–670.
29. Mitro N, Mak PA, Vargas L, Godio C, Hampton E, et al. (2007) The nuclear
receptor LXR is a glucose sensor. Nature 445: 219–223.
30. Edwards PA, Kennedy MA, Mak PA (2002) LXRs; oxysterol-activated nuclear
receptors that regulate genes controlling lipid homeostasis. Vascul Pharmacol
38: 249–256.
31. Sinal CJ, Tohkin M, Miyata M, Ward JM, Lambert G, et al. (2000) Targeted
disruption of the nuclear receptor FXR/BAR impairs bile acid and lipid
homeostasis. Cell 102: 731–744.
32. Gottlicher M, Widmark E, Li Q, Gustafsson JA (1992) Fatty acids activate a
chimera of the clofibric acid-activated receptor and the glucocorticoid receptor.
Proc Natl Acad Sci U S A 89: 4653–4657.
33. Martin PGP, Guillou H, Lasserre F, De ´jean S, Lan A, et al. (2007) Novel aspects
of PPARalpha-mediated regulation of lipid and xenobiotic metabolism revealed
through a nutrigenomic study. Hepatology 45: 767–777.
34. Van Raalte DH, Min L, Pritchard PH, Wasan KM (2004) Peroxisome
proliferator-activated receptor (PPAR)-alpha: a pharmacological target with a
promising future. Pharm Res 21: 1531–1538.
35. Vuppalanchi R, Chalasani N (2009) Nonalcoholic fatty liver disease and
nonalcoholic steatohepatitis: Selected practical issues in their evaluation and
management. Hepatology 49: 306–317.
36. Millatt LJ, Bocher V, Fruchart J-C, Staels B (2003) Liver X receptors and the
control of cholesterol homeostasis: potential therapeutic targets for the treatment
of atherosclerosis. Biochim Biophys Acta 1631: 107–118.
37. Forman, Ruan, Chen, Schroepfer, Evans (1997) The orphan nuclear receptor
LXRalpha is positively and negatively regulated by distinct products of
mevalonate metabolism. Proc Natl Acad Sci USA 94: 10588–10593.
38. Yoshikawa T, Shimano H, Amemiya-Kudo M, Yahagi N, Hasty A, et al. (2001)
Identification of liver X receptor-retinoid X receptor as an activator of the sterol
regulatory element-binding protein 1c gene promoter. Molecular and Cellular
Biology 21: 2991–3000.
39. Pawar, Botolin, Mangelsdorf, Jump (2003) The Role of Liver X Receptor-a in
the Fatty Acid Regulation of Hepatic Gene Expression. Journal of Biological
Chemistry.
40. Vega RB, Huss JM, Kelly DP (2000) The coactivator PGC-1 cooperates with
peroxisome proliferator-activated receptor alpha in transcriptional control of
nuclear genes encoding mitochondrial fatty acid oxidation enzymes. Molecular
and Cellular Biology 20: 1868–1876.
41. Son YL, Lee YC (2009) Molecular determinants of the interactions between
LXR/RXR heterodimers and TRAP220. Biochem Biophys Res Commun 384:
389–393.
42. Ide T, Shimano H, Yoshikawa T, Yahagi N, Amemiya-Kudo M, et al. (2003)
Cross-talk between peroxisome proliferator-activated receptor (PPAR) alpha and
liver X receptor (LXR) in nutritional regulation of fatty acid metabolism. II.
LXRs suppress lipid degradation gene promoters through inhibition of PPAR
signaling. Molecular Endocrinology 17: 1255–1267.
43. Yoshikawa T, Ide T, Shimano H, Yahagi N, Amemiya-Kudo M, et al. (2003)
Cross-talk between peroxisome proliferator-activated receptor (PPAR) alpha and
Naringenin: PPARa and LXRa
PLoS ONE | www.plosone.org 8 August 2010 | Volume 5 | Issue 8 | e12399liver X receptor (LXR) in nutritional regulation of fatty acid metabolism. I.
PPARs suppress sterol regulatory element binding protein-1c promoter through
inhibition of LXR signaling. Molecular Endocrinology 17: 1240–1254.
44. Miyata KS, McCaw SE, Patel HV, Rachubinski RA, Capone JP (1996) The
orphan nuclear hormone receptor LXR alpha interacts with the peroxisome
proliferator-activated receptor and inhibits peroxisome proliferator signaling.
J Biol Chem 271: 9189–9192.
45. Laffitte BA, Joseph SB, Walczak R, Pei L, Wilpitz DC, et al. (2001)
Autoregulation of the human liver X receptor alpha promoter. Molecular and
Cellular Biology 21: 7558–7568.
46. Tobin KA, Steineger HH, Alberti S, Spydevold O, Auwerx J, et al. (2000) Cross-
talk between fatty acid and cholesterol metabolism mediated by liver X receptor-
alpha. Molecular Endocrinology 14: 741–752.
47. Hu X, Li S, Wu J, Xia C, Lala D (2003) Liver X receptors interact with
corepressors to regulate gene expression. Molecular Endocrinology 17:
1019–1026.
48. Rochette-Egly C (2003) Nuclear receptors: integration of multiple signalling
pathways through phosphorylation. Cellular Signal 15: 355–356.
49. McKenna NJ, O’Malley BW (2002) Combinatorial Control of Gene Expression
by Nuclear Receptors and Coregulators. Cell 108: 465–474.
50. Wilcox LJ, Borradaile NM, de Dreu LE, Huff MW (2001) Secretion of
hepatocyte apoB is inhibited by the flavonoids, naringenin and hesperetin, via
reduced activity and expression of ACAT2 and MTP. J Lipid Res 42: 725–734.
51. Borradaile NM, de Dreu LE, Barrett PH, Huff MW (2002) Inhibition of
hepatocyte apoB secretion by naringenin: enhanced rapid intracellular
degradation independent of reduced microsomal cholesteryl esters. J Lipid Res
43: 1544–1554.
52. Allister EM, Borradaile NM, Edwards JY, Huff MW (2005) Inhibition of
microsomal triglyceride transfer protein expression and apolipoprotein B100
secretion by the citrus flavonoid naringenin and by insulin involves activation of
the mitogen-activated protein kinase pathway in hepatocytes. Diabetes 54:
1676–1683.
53. Jeon SM, Kim HK, Kim HJ, Do GM, Jeong TS, et al. (2007) Hypocholes-
terolemic and antioxidative effects of naringenin and its two metabolites in high-
cholesterol fed rats. Transl Res 149: 15–21.
54. Huong DT, Takahashi Y, Ide T (2006) Activity and mRNA levels of enzymes
involved in hepatic fatty acid oxidation in mice fed citrus flavonoids. Nutrition
(Burbank, Los Angeles County, Calif) 22: 546–552.
55. Liu L, Shan S, Zhang K, Ning Z-Q, Lu X-P, et al. (2008) Naringenin and
hesperetin, two flavonoids derived from Citrus aurantium up-regulate
transcription of adiponectin. Phytotherapy research: PTR 22: 1400–1403.
56. Chang F, Jaber LA, Berlie HD, O’Connell MB (2007) Evolution of peroxisome
proliferator-activated receptor agonists. Ann Pharmacother 41: 973–983.
57. Gastaminza P, Cheng G, Wieland S, Zhong J, Liao W, et al. (2008) Cellular
determinants of hepatitis C virus assembly, maturation, degradation, and
secretion. Journal of Virology 82: 2120–2129.
58. Huang H, Sun F, Owen DM, Li W, Chen Y, et al. (2007) Hepatitis C virus
production by human hepatocytes dependent on assembly and secretion of very
low-density lipoproteins. Proc Natl Acad Sci USA 104: 5848–5853.
59. Kim K, Kim, Kim KH, Cheong J (2008) Hepatitis B virus X protein induces
lipogenic transcription factor SREBP1 and fatty acid synthase through the
activation of nuclear receptor LXRalpha. Biochem J 416: 219–230.
60. Na T-A, Shin YK, Roh KJ, Kang SA, Hong I, et al. (2008) Liver X receptor
mediates hepatitis B virus X protein-induced lipogenesis in hepatitis B virus-
associated hepatocellular carcinoma. Hepatology 49: 1122–1131.
61. Mahmood S, Togawa K, Kawanaka M, Niiyama G, Yamada G (2008) An
Analysis of Risk Factors for Developing Hepatocellular Carcinoma in a Group of
Hepatitis C Patients with Stage 3 Fibrosis following Interferon Therapy. Cancer
Inform 6: 381–387.
62. Noguchi-Yachide T, Miyachi H, Aoyama H, Aoyama A, Makishima, et al.
(2007) Structural development of liver X receptor (LXR) antagonists derived
from thalidomide-related glucosidase inhibitors. Chem Pharm Bull 55:
1750–1754.
63. Marcus SL, Miyata KS, Zhang B, Subramani S, Rachubinski RA, et al. (1993)
Diverse peroxisome proliferator-activated receptors bind to the peroxisome
proliferator-responsive elements of the rat hydratase/dehydrogenase and fatty
acyl-CoA oxidase genes but differentially induce expression. Proc Natl Acad Sci
USA 90: 5723–5727.
64. Kidambi S, Yarmush RS, Novik E, Chao P, Yarmush ML, et al. (2009) Oxygen-
mediated enhancement of primary hepatocyte metabolism, functional polariza-
tion, gene expression, and drug clearance. Proc Natl Acad Sci U S A 106:
15714–15719.
Naringenin: PPARa and LXRa
PLoS ONE | www.plosone.org 9 August 2010 | Volume 5 | Issue 8 | e12399